Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$2.95
-C$0.11(-3.73%)
At close: 4:00 PM EDT
C$2.95
-C$0.11(-3.73%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume6.91K
Average Volume (3M)11.08K
Market Cap
C$5.16M
Enterprise ValueC$3.22
Total Cash (Recent Filing)C$250.45K
Total Debt (Recent Filing)C$15.07K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,816,565
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityExtremely low debt reduces bankruptcy risk and preserves strategic optionality for a clinical-stage firm. With minimal interest obligations, management can prioritize R&D and trial milestones over debt service, extending runway flexibility between financing events.
Narrowing Operating LossesMaterial reduction in operating losses signals improving cost structure or program prioritization. Sustained narrowing of losses improves the firm's ability to preserve cash, makes future financings less dilutive, and indicates progress toward sustainable operations if trends continue.
Focused Clinical-stage PipelineA clear, disease-focused pipeline concentrates R&D resources and expertise on kidney and metabolic indications. This specialization can create durable competitive advantages in trial design, regulator relationships, and partner interest if clinical signals emerge, improving strategic optionality.
Bears Say
No Product RevenueAbsence of recurring product revenue leaves the company dependent on external capital to fund operations and trials. Over multiple quarters, this increases financing risk and creates execution pressure: failure to raise funds or achieve milestones would materially constrain development prospects.
Persistent Negative Cash FlowSustained negative operating and free cash flows erode liquidity and force repeated financing. Even with some improvement, persistent burn reduces runway, increases dilution risk from equity raises, and limits the company's ability to scale trials or expand programs without external funding.
Shrinking Equity Base / Thin Capital CushionA materially reduced equity base reflects accumulated losses and past dilution, weakening the firm’s ability to absorb setbacks. A thinner capital cushion heightens vulnerability to adverse trial outcomes and makes future financings more dilutive, raising long-term financing risk.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.16M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 12 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -C$0.813 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.813 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.